⌘K
t
Renalytix plc announced on December 9, 2025, that all 13 resolutions at its Annual General Meeting were duly passed. Shareholders approved resolutions including the re-appointment of directors such as Christopher Mills and James McCullough, the re-appointment of PKF Littlejohn LLP as auditors, and the authorization for the issue of equity. These resolutions passed with 'for' votes ranging from 90.3% to 99.7%.
| Date | 9 Dec 2025 |
| Time | 10:57:40 |
| Category | AGMs and other meetings |
| ID | 8519K |
Renalytix plc
("Renalytix" or the "Company")
Result of AGM
LONDON and NEW YORK, 9 December 2025 - Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company, with kidneyintelX.dkd, the only FDA-approved and Medicare reimbursed prognostic test to support early-stage risk assessment in chronic kidney disease, announces that at the Annual General Meeting ("AGM") held earlier today, all resolutions were duly passed.
The results of the AGM are detailed below:
|
|
For |
% voted in favour |
Against |
% voted against |
Withheld |
|
|
Ordinary resolutions |
|
|
|
|
|
|
|
1 |
Receive and adopt the UK 2025 Annual Report |
196,930,280 |
99.7 |
587,105 |
0.3 |
20,878 |
|
2 |
Approve Directors' Remuneration Report |
195,421,372 |
98.9 |
2,073,488 |
1.1 |
43,403 |
|
3 |
Re-appointment of Christopher Mills as a Director |
178,267,303 |
90.3 |
19,130,050 |
9.7 |
140,910 |
|
4 |
Re-appointment of James McCullough as a Director |
194,129,345 |
98.3 |
3,268,008 |
1.7 |
140,910 |
|
5 |
Re-appointment of Fergus Fleming as a Director |
195,999,932 |
99.3 |
1,386,266 |
0.7 |
152,065 |
|
6 |
Re-appointment of Erik Lium as a Director |
177,457,676 |
89.9 |
19,928,522 |
10.1 |
152,065 |
|
7 |
Re-appointment of Julian Baines as a Director |
195,385,929 |
99.3 |
1,378,854 |
0.7 |
773,480 |
|
8 |
Re-appointment of Robert Naylor as a Director |
196,012,978 |
99.3 |
1,373,220 |
0.7 |
152,065 |
|
9 |
Reappoint PKF Littlejohn LLP as Auditors |
196,188,779 |
99.3 |
1,276,304 |
0.7 |
73,180 |
|
10 |
Authorise Board to determine auditors' remuneration |
196,927,685 |
99.7 |
555,598 |
0.3 |
54,980 |
|
11 |
Authorise the Issue of Equity |
195,214,647 |
98.9 |
2,147,594 |
1.1 |
176,022 |
|
|
|
|
|
|
|
|
|
Special resolutions |
|
|
|
|
|
|
|
12 |
Authorise Issue of Equity without Pre-emptive Rights |
193,317,050 |
97.9 |
4,042,090 |
2.1 |
179,123 |
|
13 |
Authorise Market Purchase of Ordinary Shares |
195,114,033 |
98.8 |
2,381,796 |
1.2 |
18,678 |
For further information, please contact:
|
Renalytix plc |
|||
|
James McCullough, CEO |
Via Walbrook PR |
||
|
|
|
||
|
SP Angel Corporate Finance LLP (Nominated Adviser and Joint Broker) |
Tel: +44 (0)20 3470 0470 |
||
|
Jeff Keating / David Hignell (Corporate Finance) Vadim Alexandre (Corporate Broking) |
|
||
|
|
|
||
|
Oberon Capital (Joint Broker) |
Tel: +44 (0)20 3179 5300 |
||
|
Mike Seabrook / Nick Lovering |
|
||
|
|
|
||
|
Walbrook PR Limited |
Tel: +44 (0)20 7933 8780 or renalytix@walbrookpr.com |
||
|
Paul McManus / Alice Woodings |
Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654 |
||
About Renalytix (www.renalytix.com)
Renalytix (LSE: RENX) (OTCQB: RNLXY) is an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes. Renalytix has received FDA approval and Medicare reimbursement for kidneyintelX.dkd which is now offered commercially in the United States.
Unrecognized and uncontrolled kidney disease remains one of the largest barriers to controlling cost and suffering in the United States and the United Kingdom's medical system, affecting approximately 15 million and 8 million people, respectively. After five years of development and clinical validation, kidneyintelX.dkd is the only FDA-approved and Medicare reimbursed prognostic tool capable of understanding a patient's risk with kidney disease early where treatment has maximal effect. kidneyintelX.dkd is now being deployed across large physician group practices and health systems in select regions of the United States.
The over 15,000 patients that have been tested by kidneyintelX.dkd have produced a substantial body of real-world performance data. In patient populations where kidneyintelX.dkd has been deployed, a demonstrated and significant increase in diagnosis, prognosis, and treatment rates have been recorded. kidneyintelX.dkd now has full reimbursement established by Medicare, the largest insurance payer in the United States, at $950 per reportable result. kidneyintelX.dkd is also recommended for use in the international chronic kidney disease clinical guidelines (KDIGO).
KidneyIntelX is based on technology developed by Mount Sinai faculty and licensed to Renalytix AI, Inc. Mount Sinai faculty members are co-founders and equity owners in the Company. In addition, the Icahn School of Medicine at Mount Sinai has equity ownership in Renalytix. For information about the kidneyintelX,dkd test, visit kidneyintelx.com.